Abstract
Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Current Vascular Pharmacology
Title:Purinergic Signalling and Endothelium
Volume: 14 Issue: 2
Author(s): Geoffrey Burnstock
Affiliation:
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Abstract: Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Export Options
About this article
Cite this article as:
Burnstock Geoffrey, Purinergic Signalling and Endothelium, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202204948
DOI https://dx.doi.org/10.2174/1570161114666151202204948 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology All for Statins and Statins for All; An Update
Current Pharmaceutical Design Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine
Current HIV Research MRI findings and renal function in patients on lithium therapy
Current Drug Safety Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) The Role of Pro-Inflammatory Molecules and Pharmacological Agents in Acute Pancreatitis and Sepsis
Inflammation & Allergy - Drug Targets (Discontinued) Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Peculiaritie of Distribution of Polymorphic Variants of IL1Β Gene in Patients with Atherosclerosis and Metabolic Syndrome
Current Pharmacogenomics and Personalized Medicine RNAi in Clinical Studies
Current Medicinal Chemistry Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Coronaviruses Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry